Citations (108)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Paul Clayton, Silma Subah, Ruchitha Venkatesh, Mariko Hill & Nathasha Bogoda. (2023) Palmitoylethanolamide: A Potential Alternative to Cannabidiol. Journal of Dietary Supplements 20:3, pages 505-530.
Read now
Read now
Dion Diep, Jasmine Ko, John Lan, Kinga T Koprowicz & Gordon Ko. (2020) Benefits, Safety, and Adjunct Modality Prevalences of Long-Term Botulinum Toxin Injections for Cervical Dystonia and Myofascial Neck Pain: A Retrospective Cohort Study. Journal of Pain Research 13, pages 1297-1304.
Read now
Read now
Franjo Grotenhermen & Kirsten Müller-Vahl. (2016) Medicinal Uses of Marijuana and Cannabinoids. Critical Reviews in Plant Sciences 35:5-6, pages 378-405.
Read now
Read now
Selim R Benbadis, Juan Sanchez-Ramos, Ali Bozorg, Melissa Giarratano, Kavita Kalidas, Lara Katzin, Derrick Robertson, Tuan Vu, Amanda Smith & Theresa Zesiewicz. (2014) Medical marijuana in neurology. Expert Review of Neurotherapeutics 14:12, pages 1453-1465.
Read now
Read now
Franjo Grotenhermen. (2004) Clinical Pharmacodynamics of Cannabinoids. Journal of Cannabis Therapeutics 4:1, pages 29-78.
Read now
Read now
KirstenR. Müller-Vahl, Udo Schneider & HinderkM. Emrich. (2002) Combined Treatment of Tourette Syndrome with Δ9-THC and Dopamine Receptor Antagonists. Journal of Cannabis Therapeutics 2:3-4, pages 145-154.
Read now
Read now
LeoE. Hollister. (2001) Marijuana (Cannabis) as Medicine. Journal of Cannabis Therapeutics 1:1, pages 5-27.
Read now
Read now
R.
Jan Gurley, Richard Aranow & Mitchell Katz. (1998) Medicinal Marijuana: A Comprehensive Review. Journal of Psychoactive Drugs 30:2, pages 137-147.
Read now
Read now
Articles from other publishers (100)
Priya Gupta, Archu Singh, Sadat Shafi, Tanya Ralli, Faheem Hyder Pottoo, Yasmin Sultana & Kanchan Kohli. (2024) Cannabis sativa in Phytotherapy: Reappraisal of Therapeutic Potential and
Regulatory Aspects. Current Pharmaceutical Biotechnology 25:1, pages 58-76.
Crossref
Crossref
Ute Hidding, Tina Mainka & Carsten Buhmann. (2023) Therapeutic use of medical Cannabis in neurological diseases: a clinical update. Journal of Neural Transmission.
Crossref
Crossref
C. Lacroix, R. Guilhaumou, J. Micallef, G. Bruneteau, C. Desnuelle & O. Blin. (2023) Cannabis for the treatment of amyotrophic lateral sclerosis: What is the patients’ view?. Revue Neurologique 179:9, pages 967-974.
Crossref
Crossref
Mauro Maccarrone, Vincenzo Di Marzo, Jürg Gertsch, Uwe Grether, Allyn C. Howlett, Tian Hua, Alexandros Makriyannis, Daniele Piomelli, Natsuo Ueda & Mario van der Stelt. (2023) Goods and Bads of the Endocannabinoid System as a Therapeutic Target: Lessons Learned after 30 Years. Pharmacological Reviews 75:5, pages 885-958.
Crossref
Crossref
Lida Du, Xiaoli He, Xiaonuo Fan, Xiaoya Wei, Linhao Xu, Tuo Liang, Chunbo Wang, Ya Ke & Wing-ho Yung. (2023) Pharmacological interventions targeting α-synuclein aggregation triggered REM sleep behavior disorder and early development of Parkinson's disease. Pharmacology & Therapeutics 249, pages 108498.
Crossref
Crossref
Nicolás Fernández, Marcello Gian Cappello & Patricia Noemí Quiroga. (2023) An assessment of qualitative and quantitative cannabinoids analysis in selected commercially available cannabis oils in Argentina. Forensic Science International 349, pages 111762.
Crossref
Crossref
Saar Anis, Achinoam Faust-Socher, Diana Sverdlov, Simon Lassman, Neomi Hezi, Omer Anis, Gil Leor, Amos D. Korczyn, Nir Giladi & Tanya Gurevich. (2023) A single-center real-life study on the use of medical cannabis in patients with dystonia. Frontiers in Neurology 14.
Crossref
Crossref
Saoirse Elizabeth O’Sullivan, Sanne Skov Jensen, Gitte Nykjaer Nikolajsen, Heidi Ziegler Bruun, Rhenu Bhuller & Julia Hoeng. (2023) The therapeutic potential of purified cannabidiol. Journal of Cannabis Research 5:1.
Crossref
Crossref
A.R. Tejeda-Martínez, J.M. Viveros-Paredes & M.E. Flores-Soto. (2022) Involvement of the Endocannabinoid System in the pathophysiology and therapeutics of movement disorders. Neurology Perspectives 2:4, pages 240-249.
Crossref
Crossref
Benzi M. Kluger, Andrew P. Huang & Janis M. Miyasaki. (2022) Cannabinoids in movement disorders. Parkinsonism & Related Disorders 102, pages 124-130.
Crossref
Crossref
WJ Maule. (2022) The therapeutic use of cannabis in South Africa: panacea or scourge?. The Journal of Medical Laboratory Science and Technology of South Africa 4:2, pages 99-107.
Crossref
Crossref
Clémence Lacroix, Isabelle Alleman-Brimault, Arnaud Zalta, Frank Rouby, Catherine Cassé-Perrot, Elisabeth Jouve, Laurence Attolini, Romain Guilhaumou, Joëlle Micallef & Olivier Blin. (2022) What Do We Know About Medical Cannabis in Neurological Disorders and What Are the Next Steps?. Frontiers in Pharmacology 13.
Crossref
Crossref
Safwat A. Ahmed, Amany K. Ibrahim, Mohamed M. Radwan, Desmond Slade, Suman Chandra, Ikhlas A. Khan & Mahmoud A. ElSohly. (2021) Microbial Biotransformation of Cannabidiol (CBD) from Cannabis sativa. Planta Medica 88:05, pages 389-397.
Crossref
Crossref
Mengya Wang, Huayuan Liu & Zegang Ma. (2022) Roles of the Cannabinoid System in the Basal Ganglia in Parkinson’s Disease. Frontiers in Cellular Neuroscience 16.
Crossref
Crossref
Pichet Termsarasab & Steven J Frucht. 2022. Comprehensive Pharmacology. Comprehensive Pharmacology
3
17
.
Vidyasagar Naik Bukke, Moola Archana, Rosanna Villani, Gaetano Serviddio & Tommaso Cassano. (2021) Pharmacological and Toxicological Effects of Phytocannabinoids and Recreational Synthetic Cannabinoids: Increasing Risk of Public Health. Pharmaceuticals 14:10, pages 965.
Crossref
Crossref
KRISTEN C. COCHRANE-SNYMAN, CANDELARIA CRUZ, JACOBO MORALES & MICHAEL COLES. (2021) The Effects of Cannabidiol Oil on Noninvasive Measures of Muscle Damage in Men. Medicine & Science in Sports & Exercise 53:7, pages 1460-1472.
Crossref
Crossref
Shah Khalid, Faisal A. Almalki, Taibi Ben Hadda, Ammar Bader, Tareq Abu-Izneid, Malika Berredjem, Eman R. Elsharkawy & Ali M. Alqahtani. (2021) Medicinal Applications of Cannabinoids Extracted from Cannabis sativa (L.): A New Route in the Fight Against COVID-19?. Current Pharmaceutical Design 27:13, pages 1564-1578.
Crossref
Crossref
Sonia Maria Dozzi BRUCKI, Tarso ADONI, Carlos Mauricio Oliveira ALMEIDA, Daniel Ciampi de ANDRADE, Renato ANGHINAH, Luciana Mendonça BARBOSA, Rodrigo BAZAN, Alzira Alves de Siqueira CARVALHO, William CARVALHO, Paulo Pereira CHRISTO, Marcus Della COLETTA, Adriana Bastos CONFORTO, Ylmar CORREA-NETO, Eliasz ENGELHARDT, Marcondes Cavalcante FRANÇA JUNIOR, Clelia FRANCO, Felipe VON GLEHN, Helio Rodrigues GOMES, Caroline Gomes de Barros HOULY, Alexandre Ottoni KAUP, Fernando KOWACS, Aline KANASHIRO, Victor Gonçalves LOPES, Débora MAIA, Maria MANREZA, Alberto Rolim Muro MARTINEZ, Sandra Cristina Gonçalves MARTINEZ, Saulo Nardy NADER, Luciana de Oliveira NEVES, Ivan Hideyo OKAMOTO, Rogério Adas Ayres de OLIVEIRA, Fabiano de Melo PEIXOTO, Cristiana Borges PEREIRA, Roberta Arb SABA, Leticia Pereira de Brito SAMPAIO, Lucas Porcello SCHILLING, Marcus Tulius Teixeira SILVA, Emanuelle Roberta SILVA, Jerusa SMID, Cristiane Nascimento SOARES, Manoel SOBREIRA-NETO, Nise Alessandra de Carvalho SOUSA, Leonardo Cruz de SOUZA, Hélio Afonso Ghizoni TEIVE, Vera Cristina TERRA, Matheus VALE, Vitor Mendes Grise VIEIRA, Edmar ZANOTELI & Gilmar PRADO. (2021) Cannabinoids in Neurology - Position paper from Scientific Departments from Brazilian Academy of Neurology. Arquivos de Neuro-Psiquiatria 79:4, pages 354-369.
Crossref
Crossref
Irshaan Syed, Sourav Garg, Saumya Agarwal & Nupur Mohapatra. 2021. Oilseeds: Health Attributes and Food Applications. Oilseeds: Health Attributes and Food Applications
373
395
.
Felipe Patricio, Alan Axel Morales-Andrade, Aleidy Patricio-Martínez & Ilhuicamina Daniel Limón. (2020) Cannabidiol as a Therapeutic Target: Evidence of its Neuroprotective and Neuromodulatory Function in Parkinson’s Disease. Frontiers in Pharmacology 11.
Crossref
Crossref
Ian O. Bledsoe, Aaron C. Viser & Marta San Luciano. (2020) Treatment of Dystonia: Medications, Neurotoxins, Neuromodulation, and Rehabilitation. Neurotherapeutics 17:4, pages 1622-1644.
Crossref
Crossref
Aleksandra Kicman & Marek Toczek. (2020) The Effects of Cannabidiol, a Non-Intoxicating Compound of Cannabis, on the Cardiovascular System in Health and Disease. International Journal of Molecular Sciences 21:18, pages 6740.
Crossref
Crossref
Marcello Mario Mascia, Daniele Carmagnini & Giovanni Defazio. (2019) Cannabinoids and dystonia: an issue yet to be defined. Neurological Sciences 41:4, pages 783-787.
Crossref
Crossref
Jenny L. Wilson, Allison Gregory, Katrina Wakeman, Alison Freed, Puneet Rai, Colin Roberts, Susan J. Hayflick & Pennylope Hogarth. (2019) Cannabis Use in Children With Pantothenate Kinase–Associated Neurodegeneration. Journal of Child Neurology 35:4, pages 259-264.
Crossref
Crossref
Anne X. Nguyen & Albert Y. Wu. (2019) Association between cannabis and the eyelids: A comprehensive review. Clinical & Experimental Ophthalmology 48:2, pages 230-239.
Crossref
Crossref
Christopher S. Pauli, Matthieu Conroy, Brian D. Vanden Heuvel & Sang-Hyuck Park. (2020) Cannabidiol Drugs Clinical Trial Outcomes and Adverse Effects. Frontiers in Pharmacology 11.
Crossref
Crossref
Qi-Wen Han, Yu-He Yuan & Nai-Hong Chen. (2020) The therapeutic role of cannabinoid receptors and its agonists or antagonists in Parkinson's disease. Progress in Neuro-Psychopharmacology and Biological Psychiatry 96, pages 109745.
Crossref
Crossref
Nilson Carlos Ferreira Junior, Maurício dos- Santos-Pereira, Francisco Silveira Guimarães & Elaine Del Bel. (2019) Cannabidiol and Cannabinoid Compounds as Potential Strategies for Treating Parkinson’s Disease and l-DOPA-Induced Dyskinesia. Neurotoxicity Research 37:1, pages 12-29.
Crossref
Crossref
Tyler E. Gaston, Jerzy P. Szaflarski, Allen C. Bowling, Ying Liu, Tristan Seawalt, Maureen A. Leehey, E. Lee Nelson, Sharad Rajpal, Alan T. Villavicencio, Andrew Bauer & Sigita Burneikiene. 2020. Cannabis in Medicine. Cannabis in Medicine
231
312
.
Anthony M. Downs, Kaitlyn M. Roman, Simone A. Campbell, Antonio Pisani, Ellen J. Hess & Paola Bonsi. (2019) The neurobiological basis for novel experimental therapeutics in dystonia. Neurobiology of Disease 130, pages 104526.
Crossref
Crossref
S.A. Millar, N.L. Stone, Z.D. Bellman, A.S. Yates, T.J. England & S.E. O'Sullivan. (2019) A systematic review of cannabidiol dosing in clinical populations. British Journal of Clinical Pharmacology 85:9, pages 1888-1900.
Crossref
Crossref
Joana Gonçalves, Tiago Rosado, Sofia Soares, Ana Simão, Débora Caramelo, Ângelo Luís, Nicolás Fernández, Mário Barroso, Eugenia Gallardo & Ana Duarte. (2019) Cannabis and Its Secondary Metabolites: Their Use as Therapeutic Drugs, Toxicological Aspects, and Analytical Determination. Medicines 6:1, pages 31.
Crossref
Crossref
Peter Riedel & Michael H. Marino. (2018) Pharmacologic Treatment Tools. Physical Medicine and Rehabilitation Clinics of North America 29:3, pages 501-517.
Crossref
Crossref
Eric P. Baron. (2018) Medicinal Properties of Cannabinoids, Terpenes, and Flavonoids in Cannabis, and Benefits in Migraine, Headache, and Pain: An Update on Current Evidence and Cannabis Science. Headache: The Journal of Head and Face Pain 58:7, pages 1139-1186.
Crossref
Crossref
Fernanda F. Peres, Alvaro C. Lima, Jaime E. C. Hallak, José A. Crippa, Regina H. Silva & Vanessa C. Abílio. (2018) Cannabidiol as a Promising Strategy to Treat and Prevent Movement Disorders?. Frontiers in Pharmacology 9.
Crossref
Crossref
Balapal S. Basavarajappa, Madhu Shivakumar, Vikram Joshi & Shivakumar Subbanna. (2017) Endocannabinoid system in neurodegenerative disorders. Journal of Neurochemistry 142:5, pages 624-648.
Crossref
Crossref
Salahaden R. Sultan, Sophie A. Millar, Timothy J. England & Saoirse E. O'Sullivan. (2017) A Systematic Review and Meta-Analysis of the Haemodynamic Effects of Cannabidiol. Frontiers in Pharmacology 8.
Crossref
Crossref
G. Todd & J.M. White. 2017. Handbook of Cannabis and Related Pathologies. Handbook of Cannabis and Related Pathologies
372
378
.
Pichet Termsarasab, Thananan Thammongkolchai & Steven J. Frucht. (2016) Medical treatment of dystonia. Journal of Clinical Movement Disorders 3:1.
Crossref
Crossref
David Trainor, Lois Evans & Rupert Bird. (2016)
Severe motor and vocal tics controlled with Sativex
®
. Australasian Psychiatry 24:6, pages 541-544.
Crossref
Crossref
Alessia Ligresti, Luciano De Petrocellis & Vincenzo Di Marzo. (2016) From Phytocannabinoids to Cannabinoid Receptors and Endocannabinoids: Pleiotropic Physiological and Pathological Roles Through Complex Pharmacology. Physiological Reviews 96:4, pages 1593-1659.
Crossref
Crossref
Fernanda F. Peres, Raquel Levin, Mayra A. Suiama, Mariana C. Diana, Douglas A. Gouvêa, Valéria Almeida, Camila M. Santos, Lisandro Lungato, Antônio W. Zuardi, Jaime E. C. Hallak, José A. Crippa, D’Almeida Vânia, Regina H. Silva & Vanessa C. Abílio. (2016) Cannabidiol Prevents Motor and Cognitive Impairments Induced by Reserpine in Rats. Frontiers in Pharmacology 7.
Crossref
Crossref
Kelly Andrzejewski, Richard Barbano & Jonathan Mink. (2016) Cannabinoids in the treatment of movement disorders: A systematic review of case series and clinical trials. Basal Ganglia 6:3, pages 173-181.
Crossref
Crossref
Mariana Babayeva, Haregewein Assefa, Paramita Basu, Sanjeda Chumki & Zvi Loewy. (2016) Marijuana Compounds: A Nonconventional Approach to Parkinson’s Disease Therapy. Parkinson's Disease 2016, pages 1-19.
Crossref
Crossref
Patrycja Kleczkowska, Irena Smaga, Małgorzata Filip & Magdalena Bujalska-Zadrozny. (2015) Cannabinoid Ligands and Alcohol Addiction: A Promising Therapeutic Tool or a Humbug?. Neurotoxicity Research 29:1, pages 173-196.
Crossref
Crossref
Barbara S. Koppel. (2015) Cannabis in the Treatment of Dystonia, Dyskinesias, and Tics. Neurotherapeutics 12:4, pages 788-792.
Crossref
Crossref
Francesco Di Pierro. (2015) A nutraceutical role for cannabidiol. Why not?. Nutrafoods 14:3, pages 111-117.
Crossref
Crossref
Briony Catlow & Juan Sanchez-Ramos. (2015) Cannabinoids for the Treatment of Movement Disorders. Current Treatment Options in Neurology 17:9.
Crossref
Crossref
Eric P. Baron. (2015) Comprehensive Review of Medicinal Marijuana, Cannabinoids, and Therapeutic Implications in Medicine and Headache: What a Long Strange Trip It's Been …. Headache: The Journal of Head and Face Pain 55:6, pages 885-916.
Crossref
Crossref
Benzi Kluger, Piera Triolo, Wallace Jones & Joseph Jankovic. (2015) The therapeutic potential of cannabinoids for movement disorders. Movement Disorders 30:3, pages 313-327.
Crossref
Crossref
Javier Fernández-Ruiz, Mariluz Hernández & Yolanda García-Movellán. 2014. Cannabinoids. Cannabinoids
175
218
.
Felipe V. Gomes, Elaine A. Del Bel & Francisco S. Guimarães. (2013) Cannabidiol attenuates catalepsy induced by distinct pharmacological mechanisms via 5-HT1A receptor activation in mice. Progress in Neuro-Psychopharmacology and Biological Psychiatry 46, pages 43-47.
Crossref
Crossref
Javier Fernández-Ruiz, Onintza Sagredo, M. Ruth Pazos, Concepción García, Roger Pertwee, Raphael Mechoulam & José Martínez-Orgado. (2013) Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid?. British Journal of Clinical Pharmacology 75:2, pages 323-333.
Crossref
Crossref
Andrew J. Hill, Claire M. Williams, Benjamin J. Whalley & Gary J. Stephens. (2012) Phytocannabinoids as novel therapeutic agents in CNS disorders. Pharmacology & Therapeutics 133:1, pages 79-97.
Crossref
Crossref
Susan H. Fox & Jonathan M. Brotchie. 2011. Parkinson's Disease. Parkinson's Disease
432
454
.
C. Zadikoff, P.M. Wadia, J. Miyasaki, R. Chen, A.E. Lang, J. So & S.H. Fox. (2011) Cannabinoid, CB1 agonists in cervical dystonia: Failure in a phase IIa randomized controlled trial. Basal Ganglia 1:2, pages 91-95.
Crossref
Crossref
E L Karschner, W D Darwin, R P McMahon, F Liu, S Wright, R S Goodwin & M A Huestis. (2011) Subjective and Physiological Effects After Controlled Sativex and Oral THC Administration. Clinical Pharmacology & Therapeutics 89:3, pages 400-407.
Crossref
Crossref
Morten V. Madsen, Linda P. Peacock, Thomas Werge, Maibritt B. Andersen & Jesper T. Andreasen. (2011) Effects of cannabinoid CB1 receptor agonism and antagonism on SKF81297-induced dyskinesia and haloperidol-induced dystonia in Cebus apella monkeys. Neuropharmacology 60:2-3, pages 418-422.
Crossref
Crossref
Sebastian Walther & Michael Halpern. (2010) Cannabinoids and Dementia: A Review of Clinical and Preclinical Data. Pharmaceuticals 3:8, pages 2689-2708.
Crossref
Crossref
Audra L Stinchcomb, Satyanarayana Valiveti, Dana C Hammell & Diana R Ramsey. (2004) Human skin permeation of Δ8-tetrahydrocannabinol, cannabidiol and cannabinol. Journal of Pharmacy and Pharmacology 56:3, pages 291-297.
Crossref
Crossref
Caterina Scuderi, Daniele De Filippis, Teresa Iuvone, Angelo Blasio, Antonio Steardo & Giuseppe Esposito. (2009) Cannabidiol in medicine: a review of its therapeutic potential in CNS disorders. Phytotherapy Research 23:5, pages 597-602.
Crossref
Crossref
Teresa Iuvone, Giuseppe Esposito, Daniele De Filippis, Caterina Scuderi & Luca Steardo. (2009) Cannabidiol: A Promising Drug for Neurodegenerative Disorders?. CNS Neuroscience & Therapeutics 15:1, pages 65-75.
Crossref
Crossref
Antonio Waldo Zuardi. (2008) Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action. Revista Brasileira de Psiquiatria 30:3, pages 271-280.
Crossref
Crossref
U. Schneider, J. Seifert, M. Karst, J. Schlimme, K. Cimander & K. R. Müller-Vahl. (2005) Das endogene CannabinoidsystemThe endogenous cannabinoid system. Der Nervenarzt 76:9, pages 1062-1076.
Crossref
Crossref
Mario Stelt, Susan H. Fox, Michael Hill, Alan R. Crossman, Stefania Petrosino, Vincenzo Di Marzo & Jonathan M. Brotchie. (2005) A role for endocannabinoids in the generation of parkinsonism and levodopa‐induced dyskinesia in MPTP‐lesioned non‐human primate models of Parkinson's disease. The FASEB Journal 19:9, pages 1140-1142.
Crossref
Crossref
Roger G. Pertwee. 2005. Cannabinoids as Therapeutics. Cannabinoids as Therapeutics
47
65
.
P. Robson. 2005. Cannabinoids. Cannabinoids
719
756
.
L.H. Shi, F. Luo, D.J. Woodward & J.Y. Chang. (2005) Dose and behavioral context dependent inhibition of movement and basal ganglia neural activity by ??9-tetrahydrocannabinol during spontaneous and treadmill locomotion tasks in rats. Synapse 55:1, pages 1-16.
Crossref
Crossref
M. Claudia Uribe Roca, Federico Micheli & Ricardo Viotti. (2005)
Cannabis sativa
and dystonia secondary to Wilson's disease
. Movement Disorders 20:1, pages 113-115.
Crossref
Crossref
C. B. CarrollP. G. BainL. TeareX. LiuC. JointC. WroathS. G. ParkinP. FoxD. WrightJ. HobartJ. P. Zajicek. (2004) Cannabis for dyskinesia in Parkinson disease. Neurology 63:7, pages 1245-1250.
Crossref
Crossref
C. ScullyJ.-V. Bagan. (2016)
A
dverse
D
rug
R
eactions in the
O
rofacial
R
egion
. Critical Reviews in Oral Biology & Medicine 15:4, pages 221-239.
Crossref
Crossref
Anthony N. Nicholson, Claire Turner, Barbara M. Stone & Philip J. Robson. (2004) Effect of Δ-9-Tetrahydrocannabinol and Cannabidiol on Nocturnal Sleep and Early-Morning Behavior in Young Adults. Journal of Clinical Psychopharmacology 24:3, pages 305-313.
Crossref
Crossref
C Scully CBE. (2003) Drug effects on salivary glands: dry mouth. Oral Diseases 9:4, pages 165-176.
Crossref
Crossref
Franjo Grotenhermen. (2003) Pharmacokinetics and Pharmacodynamics of Cannabinoids. Clinical Pharmacokinetics 42:4, pages 327-360.
Crossref
Crossref
Angelika Richter & Wolfgang Löscher. (2002) Effects of pharmacological manipulations of cannabinoid receptors on severity of dystonia in a genetic model of paroxysmal dyskinesia. European Journal of Pharmacology 454:2-3, pages 145-151.
Crossref
Crossref
Susan H. Fox, Brian Henry, Michael Hill, Alan Crossman & Jonathan Brotchie. (2002) Stimulation of cannabinoid receptors reduces levodopa‐induced dyskinesia in the MPTP‐lesioned nonhuman primate model of Parkinson's disease. Movement Disorders 17:6, pages 1180-1187.
Crossref
Crossref
Susan H. Fox, Mark Kellett, A. Peter Moore, Alan R. Crossman & Jonathan M. Brotchie. (2002) Randomised, double-blind, placebo-controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystonia. Movement Disorders 17:1, pages 145-149.
Crossref
Crossref
Elizabeth M. Williamson & Fred J. Evans. (2000) Cannabinoids in Clinical Practice. Drugs 60:6, pages 1303-1314.
Crossref
Crossref
Kirsten R. M�ller-Vahl, Udo Schneider & Hinderk M. Emrich. (1999) Nabilone increases choreatic movements in Huntington's disease. Movement Disorders 14:6, pages 1038-1040.
Crossref
Crossref
D Gadzicki, K Müller-Vahl & M Stuhrmann. (1999) A frequent polymorphism in the coding exon of the human cannabinoid receptor (CNR1) gene. Molecular and Cellular Probes 13:4, pages 321-323.
Crossref
Crossref
C. H. ASHTON. (2006) Biomedical benefits of cannabinoids?. Addiction Biology 4:2, pages 111-126.
Crossref
Crossref
K. R. Müller-Vahl, H. Kolbe, U. Schneider & H. M. Emrich. (1998) Cannabinoids: possible role in patho-physiology and therapy of Gilles de la Tourette syndrome. Acta Psychiatrica Scandinavica 98:6, pages 502-506.
Crossref
Crossref
Paul Consroe. (1998) Brain Cannabinoid Systems as Targets for the Therapy of Neurological Disorders. Neurobiology of Disease 5:6, pages 534-551.
Crossref
Crossref
Fernando Rodrı́guez de Fonseca, Ignacio Del Arco, José Luis Martı́n-Calderón, Miguel Angel Gorriti & Miguel Navarro. (1998) Role of the Endogenous Cannabinoid System in the Regulation of Motor Activity. Neurobiology of Disease 5:6, pages 483-501.
Crossref
Crossref
Angelika Richter & Wolfgang Löscher. (1998) Pathophysiology of idiopathic dystonia: findings from genetic animal models. Progress in Neurobiology 54:6, pages 633-677.
Crossref
Crossref
Futoshi Taura, Satoshi Morimoto & Yukihiro Shoyama. (1996) Purification and Characterization of Cannabidiolic-acid Synthase from Cannabis sativa L.. Journal of Biological Chemistry 271:29, pages 17411-17416.
Crossref
Crossref
Lisa A. Anderson, Jeffrey J. Anderson, Thomas N. Chase & Judith R. Walters. (1995) The cannabinoid agonists WIN 55,212-2 and CP 55,940 attenuate rotational behavior induced by a dopamine D1 but not a D2 agonist in rats with unilateral lesions of the nigrostriatal pathway. Brain Research 691:1-2, pages 106-114.
Crossref
Crossref
Angelika Richter & Wolfgang Löscher. (1994) (+)-WIN 55,212-2, a novel cannabinoid receptor agonist, exerts antidystonic effects in mutant dystonic hamsters. European Journal of Pharmacology 264:3, pages 371-377.
Crossref
Crossref
M. Navarro, F.Rodríguez De Fonseca, M.L. Hernández, J.A. Ramos & J.J. Fernández-Ruiz. (1994) Motor behavior and nigrostriatal dopaminergic activity in adult rats perinatally exposed to cannabinoids. Pharmacology Biochemistry and Behavior 47:1, pages 47-58.
Crossref
Crossref
M. Navarro, J.J. Fernández-Ruiz, R. de Miguel, M.L. Hernández, M. Cebeira & J.A. Ramos. (1993) An acute dose of δ9-tetrahydrocannabinol affects behavioral and neurochemical indices of mesolimbic dopaminergic activity. Behavioural Brain Research 57:1, pages 37-46.
Crossref
Crossref
Mark Hemming & Peter M. Yellowlees. (2016) Effective treatment of Tourette's syndrome with marijuana. Journal of Psychopharmacology 7:4, pages 389-391.
Crossref
Crossref
F. Rodríguez De Fonseca, J.J. Fernández-Ruiz, L.L. Murphy, M. Cebeira, R.W. Steger, J.A. Artke & J.A. Ramos. (1992) Acute effects of δ-9-tetrahydrocannabinol on dopaminergic activity in several rat brain areas. Pharmacology Biochemistry and Behavior 42:2, pages 269-275.
Crossref
Crossref
F.Rodríguez De Fonseca, M.L. Hernández, R. De Miguel, J.J. Fernández-Ruiz & J.A. Ramos. (1992) Early changes in the development of dopaminergic neurotransmission after maternal exposure to cannabinoids. Pharmacology Biochemistry and Behavior 41:3, pages 469-474.
Crossref
Crossref
Paul Consroe, Joan Laguna, James Allender, Stuart Snider, Lawrence Stern, Reuven Sandyk, Kurt Kennedy & Karl Schram. (1991) Controlled clinical trial of cannabidiol in Huntington's disease. Pharmacology Biochemistry and Behavior 40:3, pages 701-708.
Crossref
Crossref
Paul Consroe, Kurt Kennedy & Karl Schram. (1991) Assay of plasma cannabidiol by capillary gas chromatography/ion trap mass spectroscopy following high-dose repeated daily oral administration in humans. Pharmacology Biochemistry and Behavior 40:3, pages 517-522.
Crossref
Crossref
F. Rodríguez de Fonseca, M. Cebeira, J.J. Fernández-Ruiz, M. Navarro & J.A. Ramos. (1991) Effects of pre- and perinatal exposure to hashish extracts on the ontogeny of brain dopaminergic neurons. Neuroscience 43:2-3, pages 713-723.
Crossref
Crossref
D.E. Moss, Patricia Z. Manderscheid, S.P. Montgomery, Andrew B. Norman & Paul R. Sanberg. (1989) Nicotine and cannabinoids as adjuncts to neuroleptics in the treatment of tourette syndrome and other motor disorders. Life Sciences 44:21, pages 1521-1525.
Crossref
Crossref
E. A. Formukong, A. T. Evans & F. J. Evans. (1989) The medicinal uses of cannabis and its constituents. Phytotherapy Research 3:6, pages 219-231.
Crossref
Crossref
Edith G. McGeer & Patrick L. McGeer. (2015) The Dystonias. Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques 15:4, pages 447-483.
Crossref
Crossref